THURSDAY 10th October

9.00 – 10.00 Registration Opens & Coffee

10:00 – 12:10 SESSION 1 – Chairpersons – Paul Harrison & Alan Gadisseur

10:00 – 10.40 NETS AND THROMBOSIS. Alex Brill, University of Birmingham, UK

10.40 – 10.55 O1 TARGETING DNA AND HISTONES AS PROTHROMBOTIC STABILIZERS OF FIBRIN CLOTS CONTAINING NEUTROPHIL EXTRACELLULAR TRAPS (NETS). Colin Longstaff, Imre Varjú, Krasimir Kolev Biotherapeutics, Haemostasis Section, National Institute for Biological Standards and Control, South Mimms, Potters Bar, UK. Department of Medical Biochemistry, Semmelweis University, Budapest, Hungary

10:55 – 11.10 O2 HAEMOSTATIC AND INFLAMMATORY MARKERS AND FACTOR V LEIDEN ARE ASSOCIATED AT LEAST AS STRONGLY WITH TOTAL MORTALITY AS WITH CARDIOVASCULAR DISEASE : THE SCOTTISH HEART HEALTH EXTENDED COHORT STUDY Gordon Lowe, Sanne Peters, Ann Rumley, Hugh Tunstall-Pedoe, Mark Woodward. Institute for Cardiovascular and Medical Sciences, University of Glasgow, UK; The George Institute for Global Health, University of Sydney, Australia; and Cardiovascular Epidemiology Unit, University of Dundee, Dundee, UK.

11:10 – 11.25 O3 THROMBIN GENERATION AS MEASURED BY CALIBRATED AUTOMATED THROMBOGRAPHY (CAT) IS A PREDICTOR FOR VENOUS THROMBOSIS RECURRENCE. Catherine N. Bagot, Emma Leishman, R. Campbell Tait, Department of Haematology, Royal Infirmary, Glasgow, UK

11.25 – 11.40 O4 FATAL VENOUS THROMBOEMBOLISM ASSOCIATED WITH HOSPITAL ADMISSION: A COHORT STUDY TO ASSESS THE IMPACT OF A NATIONAL RISK ASSESSMENT TARGET. Will Lester, Nick Freemantle, Irena Begaj, Daniel Ray, John Wood, Domenico Pagano. Quality and Outcomes Research Unit, University Hospitals Birmingham, UK. School of Clinical and Experimental Medicine, University of Birmingham, UK. Department of Primary Care & Population Health, University College London, UK.

11.40 – 11.55 O5 LIPOPROTEIN-BOUND TISSUE FACTOR PATHWAY INHIBITOR IS AN EFFECTIVE INHIBITOR OF COAGULATION THROUGH DIRECT INHIBITION OF FACTOR Xa. Josefin Ahnström, Vithyaa Nithiyananthan, Dilip Patel, James TB Crawley, David A Lane Centre for Haematology, Faculty of Medicine, Imperial College
11.55 – 12.10 O6 DELAYED POST TRAUMATIC BLEEDING ASSOCIATED WITH A NEW STOP CODON IN THROMBOMODULIN Jonathan Langdown, Roger J Luddington, Jessie Fletcher, Nazia Hussain, Stephen MacDonald, Kingsley Lawrence, David J Perry, James A. Huntington* and Trevor P. Baglin. Cambridge Haemophilia and Thrombophilia Centre Addenbrooke's Hospital Cambridge University Hospitals NHS Foundation Trust Hills Road, Cambridge, UK, University of Cambridge, Department of Haematology, Cambridge Institute for Medical Research, Hills Road, Cambridge, UK.

12.10 – 12.40 BSHT AGM – BSHT members only (Lunch available for non members)

12.40 – 13.40 LUNCH, EXHIBITION & coffee/tea & poster viewing

13.40 – 15.20 SESSION 2 – Chairpersons – Robert Ariens and Jim Crawley

13.40 – 14.20 FIBRIN AND CANCER. John Biggerstaff, University of Tennessee, USA

14.20 – 14.35 O7 PLASMINOGEN PREFERENTIALLY BINDS TO PLATELET-ASSOCIATED FIBRIN Claire S Whyte, Frauke Swieringa, Johan WM Heemskerk, Nicola J Mutch. School of Medicine & Dentistry, Institute of Medical Sciences, University of Aberdeen, Aberdeen, UK; Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM) Maastricht University, The Netherlands

14.35 – 14.50 O8 FIBRINOGEN α-CHAIN AND γ-CHAIN PLAY SPECIFIC ROLES IN FIBRIN CLOT FORMATION AND STRUCTURE Cédric Duval, Victoria Ridger, Helen Philippou, Robert Ariëns. Theme Thrombosis; Division of Cardiovascular and Diabetes Research; The Leeds Institute of Genetics, Health and Therapeutics; University of Leeds; UK. Department of Cardiovascular Science; Faculty of Medicine, Dentistry and Health; University of Sheffield; UK.

14.50 – 15.05 O9 PLATELET FACTOR XIII EXERTS ANTIFIBRINOLYTIC ACTIVITY JL Mitchell, AS Lionikiene, SR Fraser, NA Booth, NJ Mutch, Institute of Medical Sciences, University of Aberdeen, Aberdeen, UK.

15.05 – 15.20 O10 EFFECTIVE CONCENTRATION OF TRANEXAMIC ACID FOR IN-VITRO INHIBITION OF FIBRINOLYSIS INDUCED BY TISSUE-TYPE PLASMINOGEN ACTIVATOR. Rozen L, Faraoni D, Willems A, Nouhouossie D, Demulder A. Laboratory of coagulation, Centre Hospitalier Universitaire (CHU) Brugmann - Queen Fabiola Children's University Hospital, Free University of Brussels, Brussels, Belgium. Department of Anesthesiology, Queen Fabiola Children’s University Hospital, Free University of Brussels, Brussels, Belgium.

15.20 – 15.50 Coffee Break and EXHIBITION

15.50 – 17.15 SESSION 3 Chairpersons Sue Pavord and Hans Deckmyn
15.50 – 16.30 AIR POLLUTION AND THROMBOSIS. Mark Hoylaerts, University of Leuven, Belgium

16.30 – 16.45 O11 TISSUE FACTOR IS RELEASED FROM CELLS WITHIN SUB-POPULATIONS OF MICROPARTICLES Camille Ettelaie, Mary EW Collier. Biomedical Section, Department of Biological Sciences, University of Hull, Cottingham Road, Hull, UK.

16.45 – 17.00 O12 IS THERE AN ASSOCIATION BETWEEN THROMBIN GENERATION (TG) AND ANTI-TISSUE FACTOR PATHWAY INHIBITOR (TFPI) ANTIBODIES IN THROMBOTIC PATIENTS WITH AND WITHOUT ANTIPHOSPHOLIPID SYNDROME M Efthymiou, AS Lawrie, IJ Mackie, SJ Machin, and H Cohen Haemostasis Research Unit, Department of Haematology, University College London, London, WC1E 6HX, UK, Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UK

17.00 – 17.15 O13 ASSOCIATION OF FXIII POLYMORPHISMS WITH ABDOMINAL AORTIC ANEURYSMS AND OVERALL SURVIVAL RATE Macrae F, Lee Evans H, Bridge KI, Sohrabi S, Johnson A, Scott DJA, Ariëns RAS. Theme Thrombosis; Division of Cardiovascular and Diabetes Research; The Leeds Institute of Genetics, Health and Therapeutics and Multidisciplinary Cardiovascular Research Centre; University of Leeds; UK

17.15 - 18.15 Poster viewing (authors to be present) & Drinks

19:15 Drinks reception at Nottinghamshire County Cricket Club

20:00 Conference Dinner in the Derek Randall Suite

FRIDAY 11th October

9.00 – 10:40 SESSION 4 Chairpersons Karen Vanhoorelbeke and Henry Watson

9.00 - 9.40 VWF and ANGIogenesis. Anna Randi, Imperial College London, UK.

9.40 - 9.55 O14 THE CRITICAL ROLE OF BAMBI (BMP AND ACTIVIN MEMBRANE BOUND INHIBITOR) IN ARTERIAL THROMBUS FORMATION UPON FERRIC CHLORIDE AND LASER INDUCED ENDOTHELIAL INJURY Isabelle I Salles, James H Monkman, Josefin Ahnstrom, David A Lane & James T.B. Crawley. Centre for Haematology, Hammersmith Hospital Campus, Imperial College London, London, UK

9.55 - 10.10 O15 A HIGH INCIDENCE OF NOVEL FLI1 AND RUNX1 MUTATIONS IN FAMILIES WITH EXCESSIVE BLEEDING AND PLATELET SECRETION DEFECTS NV Morgan, J Stockley, D Bem, GC Lowe, M Lordkipanidzé, B Dawood, MA Simpson, K Macfarlane, K Horner, VC Leo, K Talks, J Motwani, JT Wilde, PW Collins, M Makris, SP Watson and ME Daly on behalf of the UK GAPP Study Group Centre for Cardiovascular Sciences, School of Clinical and Experimental Medicine, College of Medical and Dental Sciences, University of Birmingham, UK;Department of Cardiovascular Science, University of Sheffield Medical School, University of
10.10 – 10.25 O16 EFFICACY OF THE MCMD-1 CONDENSED BLEEDING ASSESSMENT TOOL IN THE EVALUATION OF PATIENTS WITH PLATELET FUNCTION DEFECTS AND UNCLASSIFIED BLEEDING DISORDERS Tadbir K Bariana, Richard W Morris, Alison Thomas, Keith Gomez. Katherine Dormandy Haemophilia Centre and Thrombosis Unit, Royal Free Campus, University College London Medical School, Rowland Hill Street, London. UCL Medical School (Royal Free Campus), Rowland Hill Street, London, UK.

10.25 - 10.40 O17 CHARACTERISATION OF THE GAIN OF FUNCTION ADAMTS13 VARIANT R568K/F592Y/R660K/Y661F/Y665F. Kieron South, James TB Crawley, David A Lane and Brenda M Luken, Centre for Haematology, Imperial College London, London, UK.

10.40 - 10.55 O18 PLATELET REACTIVITY IN TYPE 2 DIABETES (T2DM) IS REDUCED MORE EFFECTIVELY BY ADMINISTRATION OF ASPIRIN 100 MG TWICE-DAILY THAN BY 100 MG ONCE-DAILY Harrison P, Bethel M, Sourij H, Sun Y, Tucker L, Kennedy I, White S, Hill L, Oulhaj A, Coleman RL, Holman RR. School of Immunity and Infection, University of Birmingham Medical School, Birmingham, UK, Diabetes Trials Unit, University of Oxford, Oxford, UK. Peking University People’s Hospital, Beijing, China. Department of Haematology, John Radcliffe Hospital, Oxford University Hospitals NHS Trust, Oxford, UK.

10.55 - 11.30 EXHIBITION & coffee & tea

11.30 – 12.30 Session 5 – Debate – Chairperson Sam Machin

“THERAPEUTIC OR PROPHYLACTIC PLATELET TRANSFUSION”

Hannes Wandt, Nuremberg, Germany

Andrew Mcmillan, Nottingham University Hospitals NHS Trust

12:30 – 13:30 LUNCH EXHIBITION & coffee

13.30 – 16.00 Session 6 Chairpersons – Paul Harrison & Alan Gadisseur

Scientists in Training best scoring abstracts

13.45 – 14.00 O20 THE MOLECULAR BASIS OF PROTEIN S ENHANCEMENT OF TFPI: ROLE OF THE SHBG DOMAIN Natalia Reglińska, Helena M Andersson, Suely Rezende, Björn Dahlbäck, James TB Crawley, David A Lane, Josefín Ahnström. Centre for Haematology, Faculty of Medicine, Imperial College London, Hammersmith Hospital Campus, United Kingdom. Departamento de Clínica Médica, Faculade de Medicina, Universidade Federal de Minas Gerais, Brazil. Department of Laboratory Medicine, Division of Clinical Chemistry, Faculty of Medicine, Lund University, Malmö, Sweden.

14.00 – 14.15 O21 CYTOHESIN-2 IS A NOVEL SECRETION-RELATED PKC SUBSTRATE IN PLATELETS Marion T. J. van den Bosch, Ingeborg Hers, Alastair W. Poole. School of Physiology & Pharmacology, University of Bristol, UK

14.15 – 14.30 O22 PROCOAGULANT ACTIVITY OF PLATELET-DERIVED MICROPARTICLES: A NOVEL METHOD TO DIAGNOSE HEPARIN-INDUCED THROMBOCYTOPENIA Mohammed A Alsahli, Chris Watson, Bhavesh M Popat, Kevin Horner, Barbara Hopkins, Simon Davidson, Steve Kitchen, Joost J van Veen, Sue Pavord, Gillian Swallow, Alison H Goodall. Department of Cardiovascular Sciences, University of Leicester, College of Applied Medical Sciences, Qassim University, KSA, Department of Haematology, Leicester Royal Infirmary, Department of Haematology, Sheffield Hallam Hospital, Sheffield and Royal Brompton Hospital, London, UK.

14.30 – 14.45 O23 POLYMORPHISMS OF PROTEINS INVOLVED IN FIBRINOLYSIS AND ABDOMINAL AORTIC ANEURYSMS Katherine Bridge, Fraser Macrae, Anne Johnson, D Julian Scott, Robert Ariens Theme Thrombosis; Division of Cardiovascular and Diabetes Research; The Leeds Institute of Genetics, Health and Therapeutics and Multidisciplinary Cardiovascular Research Centre; University of Leeds; UK

14.45 – 15.00 O24 IN VITRO CHARACTERISATION OF THE p.R102H MUTATION IDENTIFIED IN A PATIENT WITH CONGENITAL THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) AND DETECTABLE ADAMTS13 ANTIGEN IN THEIR PLASMA M. Underwood, I. Garagiola, I. Mackie, S. Machin, R.De Cristofaro, S.Lancellotti & F. Peyvandi. Haemostasis Research Unit, University College London, UK. Angelo Bianchi Bonomi Hemophilia and Thrombosis Centre, University of Milan. Haemostasis and Thrombosis Center, Department of Medical Sciences, Catholic University School of Medicine, Rome.

15.00 – 15.15 O25 ADAMTS13 ACTIVITY IS STIMULATED BY ANTIBODIES DIRECTED AGAINST ITS TAIL DOMAINS Louis Deforche, Elien Roose, Hanspeter Rottensteiner, Simon De Meyer and Karen Vanhoorelbeke. Laboratory for Thrombosis Research, IRF Life Sciences, KU Leuven kulak, Kortrijk, Belgium; Baxter Innovations GmbH, Vienna, Austria

15.15 – 15.30 O26 THE D187H MUTATION FOUND IN A PATIENT WITH PREGNANCY-ONSET THROMBOTIC THROMBOCYTOPENIC PURPURA IMPAIRS ADAMTS13 ACTIVITY Elien De Cock, Cedric Hermans, Karen De Ceunynck, Nele Vandeputte, Hans Deckmyn, Simon F. De Meyer, Karen Vanhoorelbeke. Laboratory for Thrombosis Research, KU Leuven Kulak, Kortrijk, Belgium Division of Haematology, Haemostasis and Thrombosis Unit, St-Luc University Hospital, Brussels, Belgium

15:30 Close of Conference
Posters

P1 SOY BEANS: THE UNKNOWN WARFARIN ANTAGONIST Andrew Senior, Miran Pankanthia, Meena Srinivasan. Princess Royal Hospital, Telford, Shropshire, UK

P2 EVALUATION OF A NEW ELISA ASSAY TO MEASURE PLATELET VASODILATOR-ASSOCIATED STIMULATED PHOSPHOPROTEIN (VASP) PHOSPHORYLATION IN PATIENTS TREATED WITH P2Y12 BLOCKERS Riveiro A, Frere C, Bonello L, Cointe S, Laine M, Pagenelli F, Dignat-George F. Laboratoire d'hématologie, CHU Conception, Assistance Publique-Hôpitaux de Marseille, Marseille. INSERM UMRS-1076, Aix Marseille University, Marseille. Laboratoire d'hématologie, CHU Timone, Assistance Publique-Hôpitaux de Marseille, Marseille. Department of Cardiology, CHU Nord, AP-HM, Marseille

P3 COMMENCING THE NEW ORAL ANTICOAGULANTS RIVAROXABAN AND DABIGATRAN – AN AUDIT OF ADHERENCE TO GUIDELINES AND PATIENT EXPERIENCE MR Wilson, CN Bagot, RC Tait. Department of Haematology, Royal Infirmary, Glasgow, UK

P4 HAEMOSTASIS TRENDS IN HIV INFECTED INDIVIDUALS L Tene, CT Tagny, A Mintya-Ndoumba, D Mbanya. Université des Montagnes, Bangangté, Cameroon ; University of Yaoundé I, Yaounde, Cameroon ; University Teaching Hospital of Yaounde, Yaounde, Cameroon.

P5 CARE HOMES: INCREASED RISK OF VTE D Goold, A Webster, S Pavord. University of Leicester Medical School. Department of Haematology, University Hospitals Leicester, UK

P6 THE USE OF THE MULTIPLATE® PLATELET FUNCTION ANALYSER IN A HAEMOPHILIA CENTRE Roger Luddington, Jessie Fletcher, Nazia Hussain, Jonathan Langdown, Stephen MacDonald and David Perry. Cambridge Haemophilia and Thrombophila centre Addenbrooke’s Hospital Cambridge University Hospitals NHS Foundation Trust Hills Road, Cambridge, UK

P7 RAPID EXCLUSION OF HEPARIN INDUCED THROMBOCYTOPENIA K. Horner, Dr J. Van Veen, Dr R. Maclean, Dr S. Kitchen. Sheffield Haemophilia and Thrombosis Centre, Sheffield, UK

P8 PERFORMANCE OF LIGHT TRANSMISSION AGGREGOMETRY (LTA) WITH THE CHRONOLOG CH 700® BEFORE IMPLEMENTATION IN A ROUTINE LABORATORY J. Vandenhoeck, I. Bacaci, L. Rozen, P. Zilimwabagabo, D. Noubouoissié, A. Demulder. Haemotology and haemostasis laboratory, CHU Brugmann, ULB Brussels, Belgium

P9 CORRELATING PROTHROMBIN TIME WITH PLASMA RIVAROXABAN LEVEL Ryan Rodgers, Catherine N. Bagot, Caroline Lawrence, Grainne Hickman, Michael McGurk and R. Campbell Tait. Department of Haematology, Glasgow Royal Infirmary, Glasgow, UK. Acute Medicine Unit, Western Infirmary, Glasgow, UK

P10 VON WILLEBRAND DISEASE; AN INTERESTING PEDIGREE WITH THREE GENETIC VARIANTS R Gooding, R Gama Paulo, R Seth, M Hill. Leicester Comprehensive Care Centre, University Hospitals of Leicester NHS Trust. Molecular Diagnostics, Nottingham University Hospitals NHS Trust

P11 COMPARING A P-SELECTIN BASED TEST WITH OTHER COMMERCIAL TESTS FOR ASSESSING PLATELET FUNCTION IN PATIENTS TREATED WITH ANTI-THROMBOTIC THERAPIES Sue Fox, Jane May, Natasha Dovlatova, Andrew Johnson, Ann White, Jackie Glenn, Yanushi Wijeyeratne, Stan Heptinstall. Cardiovascular Medicine, University of Nottingham, Queens Medical Centre, Nottingham, UK
P12 EVALUATION OF THE DIAGNOSTIC POTENTIAL OF A WHOLE BLOOD REMOTE ASSAY IN ASSESSMENT OF PLATELET FUNCTION IN BLEEDING DISORDERS Natalia Dovlatova, Marie Lordkipanidzé, Gillian C. Lowe, Jane May, Stan Heptinstall, Sue Fox and Steve Watson and on behalf of the UK GAPP Study Group. Cardiovascular Medicine, University of Nottingham, Queens Medical Centre, Nottingham, UK; Birmingham Platelet Group, University of Birmingham, Birmingham UK.

P13 EXPLORING THE PATHOGENESIS OF ANTIPLATELET ANTIBODIES IN IMMUNE THROMBOCYTOPENIA (ITP) Adrienn Orosz, Isabelle I. Salles, Shahzaib Ahmad, Nichola Cooper, James T.B. Crawley. Centre for Haematology, Imperial College London, London, UK

P14 SINGLE CENTRE OUTCOMES AFTER STILLBIRTH ASSOCIATED WITH PLACENTAL INFARCTION Sarah Wharin, Sue Pavord, Helena Maybury. Leicester Royal Infirmary, University Hospitals Leicester, UK


P16 IS THE ROBO4 VASCULAR RECEPTOR RELEASED DURING ENDOTHELIAL CELL DAMAGE ASSOCIATED WITH HEPARIN INDUCED THROMBOCYTOPENIA. T. Svermova, A. Burke-Gaffney, SJ Davidson. Department of Critical Care Medicine, Royal Brompton Hospital and National Heart and Lung Institute, Imperial College, London, UK, Department of Haematology, Royal Brompton Hospital, London, UK